Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers (IMPACT)

September 30, 2026 updated by: Mayo Clinic

This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with primary diagnosis of cancer when 15-39 years old.

Description

Inclusion Criteria:

  • Adults (aged 18+ years)
  • Primary diagnosis of cancer when 15-39 years-old
  • Access to a desktop computer or laptop with reliable internet access
  • No gross motor impairments that prohibit ambulation
  • Willing to complete study requirements
  • English speaking

Exclusion Criteria:

  • Diagnosed with nonmelanoma skin cancer only
  • Not diagnosed with cancer in adolescent and young adult (AYA) age range of 15-39 years
  • Scheduled travel during the study period that is not indicative of individual's normal schedule

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Observational

Patients complete questionnaires and cognitive tasks and wear an activity monitor to measure physical activity on study. Some patients may optionally participate in an interview on study.
Other: Non-Interventional Study

Non-Interventional Study

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Cognitive performance on Stroop task
Time Frame: Up to 4 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.
Up to 4 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Cognitive performance on Visual Memory Test
Time Frame: 2 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.
2 weeks
Cognitive performance on Verbal Memory Test
Time Frame: 2 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.
2 weeks
Cognitive performance on Symbol Digit Coding Test
Time Frame: 2 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.
2 weeks
Cognitive performance on Shifting Attention Test
Time Frame: 2 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.
2 weeks
Cognitive performance on Continuous Performance Test
Time Frame: Up to 4 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games").
Up to 4 weeks
Cognitive performance on Reasoning Test
Time Frame: 2 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.
2 weeks
Cognitive performance on Four Part Continuous Performance Test
Time Frame: 2 weeks

Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.
2 weeks
Self-reported cognition - FACT-COG
Time Frame: 2 weeks

Evaluated using the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG), a 37-item questionnaire assessing cognitive impairment, cognitive abilities, and quality of life over the past 7 days. Responses are on a 5-point scale (Never; About once a week; Two to three times a week; Nearly every day; Several times a day). Higher scores generally indicate better self-reported cognition.
2 weeks
Average weekly minutes of physical activity
Time Frame: 2 weeks

Moderate-to-vigorous physical activity (MVPA) will be measured using an accelerometer (activPAL) which participants will wear on their non-dominant thigh for 7 consecutive days.
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Mayo Clinic

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Diane K. Ehlers, PhD, Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 15, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 12, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 12, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 18, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 2, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 30, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 24-008654
  • 24-008654 (Other Identifier: Mayo Clinic Institutional Review Board)
  • NCI-2025-01193 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified, limited datasets will be shared with other researchers upon request or according to journal publication requirements

IPD Sharing Time Frame

At time of first publication (as required by journals) until last manuscript is published.

IPD Sharing Access Criteria

If required by journal and case by case upon request to the PI

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings